Extreme Movers: Muse Spark 1.1's picks for 2026-09-30
Muse Spark 1.1 picked IOVA, BE, CCL, FICO, QURE for a 1-day horizon. Average directional return: +0.35%. Directions called correctly: 60%.
| Experiment | Extreme Movers |
|---|---|
| Model | Muse Spark 1.1 |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-09-30 |
| Measured to | 2026-10-01 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | +0.35% |
| Directions called correctly | 60% |
| Benchmark return | -0.99% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | IOVA | up | +1.29% | +1.29% | 72% | +2.28% | Yes |
| 2 | BE | up | -2.69% | -2.69% | 68% | -1.69% | No |
| 3 | CCL | down | -2.30% | +2.30% | 60% | +3.30% | Yes |
| 4 | FICO | up | +6.49% | +6.49% | 65% | +7.48% | Yes |
| 5 | QURE | up | -5.64% | -5.64% | 62% | -4.65% | No |
The model's market view
September 29 session was split: large-cap indices slipped -0.17% S&P, -0.09% Nasdaq on surging long yields, while idiosyncratic catalysts drove extreme moves. Biotech and cruise were top gainers on guidance upgrades and demand, while mortgage-tech scoring and gene therapy were top losers on regulatory and clinical failures. Pre-market September 30 shows futures firmer on lower yields but still cautious into PCE/GDP at 08:30 ET and MU earnings after close, favoring mean-reversion for one-day panic sells and continuation risk for momentum biotech with raised guidance.
Why each pick
IOVA
Rank 1 gainer Sep 29: +31.48% at $14.45 on 3.3M+ shares, gapping from prior close $10.99 to open $12.79 after HC Wainwright raised target to $20 from $9. Catalyst is substantive: raised FY2026 revenue guidance to $410-420M from $350-370M on Amtagvi demand. Price $14.45 meets $5 floor, market cap ~ $6.3B meets $1B, average volume 16.7M shares ~ $180M+ dollar volume meets $20M. Using delayed intraday quote $14.45 as reference, data_date 2026-09-29 close, slightly stale but latest verified. Previous change +31.48% continuation thesis: momentum + guidance revision typically carries one more session, though up >30% raises reversal risk. Source for move and price: Zacks and TradingNews.
BE
Rank 2 gainer Sep 29: Bloom Energy closed up +10.8% at $291.25, intraday high $302.25, volume 23.69M shares far above average, after Jefferies raised target to $264 from $229. Catalyst substantive: AI data center distributed power backlog, with $77-85B market cap. Price $291.25 meets $5, market cap $74.5B to $79.3B meets $1B, 20-day avg vol 16.3M shares x ~$270 = ~$4.4B dollar volume meets $20M. Using Sep 29 regular close $291.25 as reference, latest verified before Sep 30 open. Previous change +10.8% continuation thesis: data center power demand narrative still hot, pre-market Sep 30 shows GLD and growth bounce but BE not yet faded.
CCL
Rank 3 gainer Sep 29: Carnival +13.55% at $25.14, close verified $25.11 at 4:30pm ET Sep 29. Catalyst is speculative/momentum: cruise sector bid with RCL +7.47% same day, no company-specific news cited, just sector rotation. Price $25.11 meets $5, market cap $34.39B meets $1B, dollar volume 3.8M shares x $25 = $95M meets $20M. Using Sep 29 close $25.11 as reference, data_date 2026-09-29. Previous change +13.41% reversal thesis: outsized one-day cruise move without fundamental news often mean-reverts next session, especially with Russell 2000 -0.44% and consumer softness noted.
FICO
Rank 1 loser Sep 29: Fair Isaac fell -26.52% to $617.87 close, gapped down from $840.89 prior close to $668.08 open after FHFA announced unified mortgage pricing grid opening Fannie/Freddie loans to VantageScore competition. Catalyst substantive: loss of scoring monopoly, BofA cut to Neutral. Price $617.87 meets $5, market cap ~ $20.8B down to ~$15.4B after drop meets $1B, trading turnover $3.1B on day far exceeds $20M avg. Using Sep 29 close $617.87 as latest verified quote, data_date 2026-09-29. Previous change -26.52% reversal thesis: panic sell on regulatory news often sees short-term bounce as $595.19 low tested, down 62% YTD already oversold, while continuation risk remains due to structural moat loss.
QURE
Rank 2 loser Sep 29: uniQure fell -37.33% to $24.51 at close Sep 29 4pm ET on 29.6M shares after AMT-130 Huntington's 48-month data showed smaller benefit than 3-year. Catalyst substantive: clinical efficacy fade, prompted legal investigations. Price $24.51 meets $5, market cap ~ $2.7B meets $1B, average dollar volume last month $61.479M meets $20M. Using Sep 29 close $24.51 as reference, latest verified, data_date 2026-09-29. Previous change -37.33% reversal thesis: biotech crash on single dataset often sees dead-cat bounce next session as shorts cover, though continuation down is possible if benefit erosion seen as program-ending.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Perplexity | FORM, HPE, MRNA, CEG, APP | -0.85% | 40% |
| Claude Sonnet 5.5 | CCL, IOVA, DKNG, FICO, BE | +2.16% | 80% |
| Grok 4.5 | CCL, BE, FICO, RCL, STLD | -0.10% | 20% |
| DeepSeek | CCL, FICO, IOVA, LITE, RCL | +0.15% | 40% |
| Gemini 1.5 Pro | CCL, FICO, BE, RCL, IOVA | -1.26% | 40% |
| GPT-6 | IOVA, FICO, CCL, BE, KMX | -0.26% | 60% |
Written up on ForecastNest Insights: Extreme Movers: Muse Spark 1.1's picks for 2026-09-30.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.